Skip to main content



11-12-2017 | HBV | News | Article

Partial TDF responders achieve virologic response with treatment continuation

Most patients with chronic hepatitis B virus infection initially classed as partial responders to treatment with tenofovir disoproxil fumarate achieve a virologic response without additional treatment adjustment, research suggests.

11-12-2017 | HBV | News | Article

HCC, mortality risk remains for untreated immune tolerant-phase HBV patients

Being in the immune tolerant phase of chronic hepatitis B virus (HBV) infection is no assurance against the risk for developing hepatocellular carcinoma (HCC), requiring liver transplantation, or dying, say South Korean investigators.

20-10-2017 | Oncology | Main feed | News

Nivolumab represents ‘new treatment option’ for advanced gastric cancer

Nivolumab significantly prolongs survival, versus placebo, in heavily pretreated patients with unresectable gastric or gastro-esophageal junction cancer, ATTRACTION-2 study findings indicate.

29-09-2017 | HBV | News | Article

Consensus reached on design of clinical trials for novel, curative HBV therapies

A panel of hepatitis B virus experts has issued a consensus statement intended to aid in standardizing the efficacy and safety appraisals of novel, potentially curative antiviral and immune modulatory agents.

29-09-2017 | HBV | News | Article

Novel indices to diagnose fibrosis in chronic HBV patients developed

Two research groups have developed noninvasive indices to detect significant fibrosis in treatment-naïve patients with chronic hepatitis B virus infection, one using serum levels of Golgi protein 73 and liver stiffness, and the other based on the ratio of gamma-glutamyl transpeptidase to albumin.

26-09-2017 | HBV | News | Article

Sex modifies age-related HCC risk after HBsAg clearance

Achieving hepatitis B surface antigen seroclearance neutralizes the increased risk for hepatitis B virus-related hepatocellular carcinoma among women aged 50 years or younger, but not among older women or men regardless of their age, research indicates.

26-09-2017 | HBV | News | Article

Treatment-induced liver stiffness reduction lowers HCC risk in HBV patients

Achieving a subcirrhotic liver stiffness level after antiviral therapy halves the risk for hepatocellular carcinoma in patients with chronic hepatitis B virus-related advanced fibrosis or cirrhosis, Korean research shows.

25-09-2017 | Gastrointestinal cancer | News | Article

FLOT4-AIO results could guide operable gastric cancer treatment

Perioperative docetaxel, oxaliplatin, and 5-fluorouracil/leucovorin treatment should be a new standard of care for patients with operable adenocarcinoma of the stomach or gastroesophageal junction, say the FLOT4-AIO trial investigators.

22-09-2017 | HBV | News | Article

Perinatal HBV infection ‘nearly eliminated’ with Japan’s selective vaccination program

The Japanese nationwide selective vaccination strategy has led to a substantial reduction in perinatal hepatitis B virus transmission, say researchers who evaluated the prevalence of hepatitis B surface antigen among pregnant women born before and after its implementation.

22-09-2017 | HBV | News | Article

High metabolic risk burden increases HCC risk in HBV patients

A high burden of metabolic risk factors significantly increases the risk for hepatocellular carcinoma among men with hepatitis B virus infection, particularly those who smoke, researchers from Taiwan report.

15-08-2017 | HBV | News | Article

Serum biomarkers combine to improve HCC risk stratification in HBV patients with low viremia

In patients with persistently low serum levels of hepatitis B virus DNA, the combined use of the noninvasive aspartate aminotransferase to platelet ratio index and the Fibrosis-4 index could help identify those at increased risk for developing hepatocellular carcinoma.

15-08-2017 | HBV | News | Article

HCC incidence declines with prolonged HBV treatment

The incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection declines significantly after the first 5 years of treatment with the nucleos(t)ide analogs entecavir and/or tenofovir, researchers report.

11-08-2017 | HBV | News | Article

Real-world outcomes of antiviral therapy in Asian chronic HBV patients described

Analysis of a community-based cohort comprising mainly Asian patients receiving antiviral therapy for chronic hepatitis B virus infection shows a higher rate of hepatitis B surface antigen loss than is generally reported for Asian clinical trial cohorts.

04-08-2017 | HBV | News | Article

Anti-HBc levels predict hepatic inflammation in patients with chronic HBV

Serum hepatitis B core antibody levels significantly predict hepatic inflammation in patients with chronic hepatitis B virus infection, including those with normal alanine aminotransferase levels, Chinese research shows.

27-07-2017 | HBV | News | Article

Maternal HBV infection raises preterm birth risk

Women with hepatitis B virus infection prior to becoming pregnant are significantly more likely to have a preterm birth than those without HBV, shows an analysis of a Chinese population-based cohort.

27-07-2017 | HBV | News | Article

Temporal liver cancer trends in HBV-endemic population mapped

A South Korean population-based study shows an increase in liver cancer burden over a 14-year period, while another analysis in the same population shows an improvement in the survival of patients with hepatocellular cancer in the past decade.

07-07-2017 | Colorectal cancer | News | Article

In other news: Focus on colorectal cancer

Here is a roundup of recent colorectal cancer research, ranging from diagnosis to treatment and prevention.

05-06-2017 | HBV | News | Article

Overt, occult HBV infection remains a concern despite immunization

Despite a universal program to vaccinate newborns against hepatitis B virus infection, the prevalence of overt and occult infection among children in northwest China is a cause for concern, say researchers.

05-06-2017 | HBV | News | Article

Support for TDF in patients with HBV-related decompensated cirrhosis

Among patients with hepatitis B virus-related decompensated cirrhosis, first-line tenofovir disoproxil fumarate therapy not only reduces HBV DNA levels, but also improves hepatic function, indicates a real-world South Korean study.

01-06-2017 | HBV | News | Article

Higher rate of anti-HBs disappearance with recombinant versus plasma HBV vaccine

The infant recombinant yeast hepatitis B virus vaccine has long-term efficacy, but the rate of disappearance of protective antibodies against hepatitis B surface antigen is higher than with the plasma-derived vaccine, shows a study of Taiwanese university students.

Image Credits